Loading data for GOSS — first visit, this takes a few seconds.

Alert

Gossamer Bio Inc. (GOSS)

NasdaqGS: GOSS · Real-Time Price · USD

0.17

+0.00 (0.00%)

At close: Aug 27, 2026, 8:00 PM

0.17

+2.23%

After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

0.00% (1D)

No data available

Bid	0.17
Market Cap	83.15M
Revenue (ttm)	53.29M
Net Income (ttm)	-125.22M
	2.01
	-0.66
	n/a
	-0.87
P/B (ttm)	-0.89
P/S (ttm)	1.56
Earnings Date	Nov 4, 2026

Ask	0.17
Volume	15,189,737
Avg. Volume (20D)	28,083,649
Open	0.18
Previous Close	0.17
Day's Range	0.16 - 0.18
52-Week Range	0.11 - 3.87
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It ha...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 8, 2019

Employees 161

Stock Exchange NasdaqGS

Ticker Symbol GOSS

Website https://www.gossamerbio.com

Full Company Profile

Financial Performance

In 2025, Gossamer Bio's revenue was 48.47M, a decrease of -57.74% compared to the previous year's 114.7M. Earnings were -170.37M, an increase of 201.39%.

Financial Statements

Earnings Surprise

Gossamer Bio has released their quarterly earnings on Aug 13, 2026:

Revenue of $16.95M misses estimates by $0, with 71.45% YoY growth.
EPS of -0.1 exceeds estimates by 0.02, with 41.18% YoY growth.

Next Earnings Release

Gossamer Bio Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

3 days ago · Pharmaceutical Technology

Gossamer Bio announces $250m in funding to advance seralutinib

The proceeds will help advance seralutinib's clinical development and potential commercialisation.

6 days ago · MT Newswires

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S

6 days ago · InvestorsHub

Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio has structured the financing around key seralutinib regulatory milestones, with $150 million committed and another $100 million potentially available if the pulmonary arterial hypertensio...

6 days ago · MT Newswires

Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

Gossamer Bio (GOSS) shares were up 10% in Friday's premarket trading after the company said it has a

1 week ago · Simply Wall St.

Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib

For Gossamer Bio, the average analyst Fair Value has shifted from about US$3.86 to about US$1.66 per share, which marks a meaningful reset in price targets. Research commentary links this move to a sp...

Page 1 of 2

Gossamer Bio Inc. (GOSS)